Navigation Links
Using nanomagnets to enhance medical imaging

Nanoscale magnets in the form of iron-containing molecules might be used to improve the contrast between healthy and diseased tissue in magnetic resonance imaging (MRI)—as long as the concentration of nanomagnets is carefully managed—according to a new report* by researchers at the National Institute of Standards and Technology (NIST) and collaborators. Molecular nanomagnets are a new class of MRI contrast agents that may offer significant advantages, such as versatility in design, over the compounds used today.

Contrast agents are used to highlight different tissues in the body or to help distinguish between healthy and diseased tissue. NIST is working with two universities and a hospital to design, produce and test nanomolecules that might make MRI imaging more powerful and easier to perform. The new paper resolves a debate in the literature by showing that iron-containing magnets just two nanometers wide, dissolved in water, do provide reasonable contrast in non-clinical MRI images—as long as the nanomagnet concentration is below a certain threshold. (A nanometer is one billionth of a meter.) Previous studies by other research groups had reached conflicting conclusions on the utility of molecular nanomagnets for MRI, but without accounting for concentration. NIST scientists, making novel magnetic measurements, were able to monitor the molecules' decomposition and magnetic properties as the composition was varied.

The injectable dyes currently used as MRI contrast agents are of two types. Magnetic ions, which alter the nuclear properties of hydrogen in water, offer the advantage of consistent identical design but provide low contrast. The second category encompasses particles of thousands of atoms or crystals, which alter local magnetic fields; they provide contrast variation in a larger region but have irregular designs and magnetic properties that are difficult to control. By comparison, molecular nanomagnets can be designed to have consistent
'"/>

Source:National Institute of Standards and Technology (NIST)


Page: 1 2

Related biology news :

1. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Researchers Closer To Helping Hearing-Impaired Using Stem Cells
4. Using nanoparticles, in vivo gene therapy activates brain stem cells
5. Using computers and DNA to count bacteria
6. Using the genomic shortcut to predict bacterial behavior
7. Using natures most primitive anti-viral defense system to find new approaches to cancer research
8. Using dental X-rays to detect osteoporosis
9. Using brain scans, researchers find evidence for a two-stage model of human perceptual learning
10. Amino acids in nectar enhance butterfly fecundity: A long awaited link
11. Pulsating ultrasound enhances gene therapy for tumors

Post Your Comments:
(Date:11/4/2009)..., NEW YORK, Oct. 27 Global Rainmak...y and advanced R&D laboratory, today announced...d is prepared to actively commercialize its suite ...biometric security offerings. ,, During the pas...ns of dollars to develop and deploy a series of co...
(Date:11/3/2009)..., BOCA RATON, FL (November 4, 2009) For more tha...the queen conch ( Strombus gigas ) have been unsuc...oprietary seeding techniques to produce beaded (nu...ueen conch have been developed by scientists from ...graphic Institute (HBOI). With less than two years...
(Date:11/3/2009)...,, WEST LAFAYETTE, Ind. - Chief executives i...d by about 129 times their "ideal salaries" in 200... proposed by a Purdue University researcher to det... pressing economic and corporate governance issues...for CEOs," said Venkat Venkatasubramanian, a profe...
Breaking Biology News(10 mins):Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4DuPont Adds Cotton to India Seed Product Lineup 12789 1DuPont Adds Cotton to India Seed Product Lineup 12789 2DuPont Adds Cotton to India Seed Product Lineup 12789 3DuPont Adds Cotton to India Seed Product Lineup 12789 4Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 1Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 2Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 3Wrigley Honored With 2009 Best Employers for Healthy Lifestyles Award 50084 4Nations first childrens hospital based safety store focuses on child injury prevention 50079 1Nations first childrens hospital based safety store focuses on child injury prevention 50079 2
... Researchers from the University of Minnesota Medi...polis VA Medical Center have identified a noninvas...eases. And its as simple as staring at a point of ...essful, painless, and objective diagnosis for brai...iveness of different treatments for these diseases...
... MADISON, WI, AUGUST 22, 2007- Climate change, a r...ns, and Earths surface; however, the study of anot...still very much underground. Few scientists are lo...limate change on groundwater systems. Little is kn...ater are responding to climate change. , Scientis...
... Miami, Fl (Aug 22, 2007) New research shows how ...daptations in order to transfer pollen on differen...lant species to share bats as pollinators. The st...nated flowers of the genus Burmeistera: analysis o...d in this weeks journal Proceedings of the Royal S...
Other Biology News:U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases 2Climate change goes underground 2Climate change goes underground 3How to share a bat 2
(Date:11/6/2009)...ire/ -- Myriant Technologies LLC ("Myriant"), a pr...f renewable bio-chemicals, Uhde Corporation of Am...mbH, one of the world,s leading engineering contra...the engineering, procurement & construction (E...ed on renewable feedstocks. The execution of this...
(Date:11/6/2009)...rstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDA...unced updated results from a Phase II study of int...astatic to the lung in a poster presentation at th...eeting held in Miami Beach, Florida, from November...Phase II Study of Intravenous REOLYSIN (Wild-type ...
(Date:11/5/2009)...ewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ...ird quarter ended September 30, 2009. GenVec repor...or the three months ended September 30, 2009 compa...) in the comparable quarter of 2008. For the nine ... was $14.1 million ($0.15 per share), compared to ...
(Date:11/5/2009)... ThermoGenesis Corp. (Na...oducts for processing and storing adult stem cells...fiscal 2010. ,, For the quarter ended September...illion, a 15 percent increase over revenues of $4....pany said the key contributors to the growth in re...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...c. (Amex:,ADL), developer and marketer of tests fo...diseases, announced today that it has conducted th...S private unit offering of,2,007,508 shares of com...s,of common stock, generating net proceeds of appr...ock were sold at $3.09 per share and the four year...
...,Pharmaceuticals, a division of Wyeth (NYSE: WYE ...ement claim for lost profits and other damages,aga... Teva,s launch of a,pantoprazole tablet -- a gener... disputed that its product infringes the United St... to Wyeth by Altana, recently,acquired by Nycomed,...
...ance in memory storage devices presents a new marv...ry small spaces. Considering the potential of nano... the University of California, Riverside, things a...the latest issue of Technology Review, Khizroev is... point to a future where a 10-terabit hard drive i...
Other Biology Technology:AMDL Announces Closing of Private Offering 2Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 2Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 3Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 4The Library of Congress in your wrist watch? 2
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
QCapture Pro Software from QImaging
Anti-XIAP Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: